[THE INVESTOR] Hugel will continue to gain momentum as it will be able to tap into advanced markets with its toxins and fillers, said KB Investment and Securities on Dec. 14, maintaining a “buy” recommendation and raising the target price to 620,000 won (US$571.01) from 580,000 won.
Its botulinum toxin’s phase 3 clinical trials in the US and Europe will be completed in the first half of next year and it will seek a local distribution partner, forecast analyst Seo Geun-heui.
The streamlining of business structure through merger of Hugel Pharma and Hugel Meditel scheduled for January, and the expectations for the year-end dividends also are favorable, said the analyst.
Its revenue in 2018 will rise 10.4 percent on-year to 195.1 billion won and operating profit by 8.3 percent to 111.4 billion won, estimated Seo.
By Hwang You-mee (firstname.lastname@example.org)